Physician profile
Robyn E Massa
NPI 1578820338
$10,002.12
in general payments reported to CMS, 2019-2025
59 companies · $1,897 in 2025
The $1,897 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $755 · 2021: $741 · 2022: $1,497 · 2023: $2,024 · 2024: $2,514 · 2025: $1,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,285 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,285.27 |
| Education | $149.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,920.33 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $746.05 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $598.25 | 2019-2025 | Rytary, Ongentys, Ongentys 50mg Capsules 30 |
| Ucb, INC. | $423.70 | 2019-2025 | Nayzilam, Rystiggo, Briviact |
| Lilly USA, LLC | $319.66 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Merz Pharmaceuticals, LLC | $318.14 | 2021-2025 | Xeomin, Inbrija |
| Acorda Therapeutics, INC | $315.25 | 2019-2024 | Inbrija |
| Mdd US Operations, LLC | $295.90 | 2020-2025 | Gocovri, Gocovri |
| Neurocrine Biosciences, INC. | $281.06 | 2022-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $279.68 | 2022-2025 | |
| Boston Scientific Corporation | $277.45 | 2019-2025 | General - Dbs |
| Teva Pharmaceuticals USA, INC. | $265.62 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Allergan, INC. | $214.69 | 2019-2022 | |
| Kyowa Kirin, INC. | $208.30 | 2019-2024 | Nourianz |
| Abbott Laboratories | $204.63 | 2024-2025 | Infinity |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Massa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.